- Poster presentation
- Open Access
Acoustic rhinometry after nasal provocation test, 6 months interim analysis of alumites study, a randomized, controlled, multicentre phase IV study with house dust mites subcutaneous immunotherapy
© Sanchez et al; licensee BioMed Central Ltd. 2013
- Published: 16 July 2013
- Visual Analogical Scale
- Active Group
- Allergic Rhinitis
- Interim Analysis
ALUMITES study was designed to assess the efficacy of house dust mites (HDM: D. pteronyssinus + D. farinae) subcutaneous immunotherapy for the treatment of allergic rhinitis patients along one year. Here we report an interim analysis done after 6 months of treatment.
In this controlled multicentre phase IV study, HDM adult allergic patients were randomized to receive subcutaneous immunotherapy with a 10 IR/ml depot extract plus symptomatic treatment (group A) or only symptomatic treatment (group B) (2:1). Acoustic rhinometry after nasal provocation test (NPT) was selected to objectively assess the efficacy of this treatment by measuring the nasal volume (NV) and minimum cross-sectional area (MCA). A visual analogic scale (VAS) has been used to subjectively assess the efficacy (0-10 scale, lower is better)NPT consists in 5 determinations at intervals of 15 minutes (basal, diluent, 0.01 IR, 0.1 IR, 1 IR) and one last determination 30 minutes after the last administration. The extract used for the NPT was 100 IR/ml of D. pteronyssinus.
Data from 38 of 57 patients were complete to be analyzed. MCA difference from baseline to six months visit was 1.6 cm2 (95% CI: [-2.1, 5.3]) in active group and 0.8 cm2 (95% CI: [-4.3, 5.9]) in control group. NV difference from baseline to six months visit was 37.1 cm3 (95% CI: [-16.9, 91.2]) in active group and -5.8 cm3 (95% CI: [-75.6, 64]) in control group. The analysis of covariance (ANCOVA) showed statistical differences in basal determination of MCA after 6 months treatment (p=0.0001).The symptoms score after the last provocation of 1 IR measured by VAS from baseline to the six month visit had a reduction of -2.4 points (95% CI: [-3.2, -1.6], p<0.0001) in the active group whereas there was no statistical reduction in the control group: -0.7 points (95% CI: [-2.5, 1.0], p=0.577).
Despite of the final low sample to analyze, efficacy is demonstrated with six months of SCIT treatment with 10 IR/ml depot HDM extract that resulted in a significant improve in clinical symptoms, this improvement was not achieved by the control group. Objective assessment of efficacy shows a clear positive trend in minimal cross-sectional area determination.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.